Harborview Medical Center Study – AeroEclipse II® BAN – Reduction of 30 day re-admission rate and COPD LOS
Previous Post : AeroEclipse II<sup>®</sup> BAN Efficiency StudyNext Post : AEROECLIPSE<sup>®</sup> Breath Actuated Nebulizers (BAN)
JOIN US AT ATS 2025 IN SAN FRANCISCO FROM MAY 16-21
Accessibility Tools
